Stelara Biosimilars Will Compete Not Only With J&J’s Tremfya But Also Oral IL-23 Peptide
The CEO Reaffirmed Humira As Stelara’s Market Erosion Model
At the 2025 J.P. Morgan Healthcare Conference, Johnson & Johnson outlined a new competition blueprint for anti-inflammatory biosimilars, going beyond the next blockbuster Tremfya.
